All Videos

Panelists discuss how clinicians can choose the most appropriate systemic treatment for moderate to severe atopic dermatitis by evaluating patient characteristics, comorbidities, and therapeutic goals while considering the latest clinical evidence.

Patrick Burnett, MD, PhD, shares key updates expected in 2025 for therapeutics treating atopic dermatitis, alopecia areata, and more.

The panelist discusses how to safely transition a 36-year-old man with a history of systemic corticosteroid use to appropriate oral treatment options while monitoring for potential complications.

The panelist discusses how to evaluate the need for and manage the transition between biologic therapies in a 32-year-old woman with severe atopic dermatitis who has had an inadequate response to initial treatment.

Robinson shared insights into how the company is working to fight clinical research disparities.

Dustin Portela, DO, discuss how Swift microwave therapy can enhance patient care, generate referrals, and offer a promising revenue stream, while keeping pace with ongoing advancements in the technology.

Dustin Portela, DO, highlights how the design of Swift microwave therapy improves efficiency, simplifies training for medical assistants, and enhances practice flexibility.

In this episode, Dustin Portela, DO, explores how Swift microwave therapy enhances efficiency and allows physicians to focus on other aspects of care.

Dustin Portela, DO, discusses patient selection and affordability considerations for Swift microwave therapy. He explores how the treatment process works and strategies to ensure patient comfort during sessions.

In this episode, Dustin Portela, DO, explores how Swift microwave therapy is transforming wart treatment, the science behind this technology, and how it reduces wart-related pain.

In this episode, Dustin Portela, DO, discusses how treating warts can be a challenge and explores the effectiveness of Swift microwave therapy. The episode reviews how this innovative approach compares to traditional methods and helps patients achieve lasting results.

An expert discusses how treatment for alopecia areata begins with topical/intralesional therapies for limited disease and progresses to systemic options for extensive involvement or treatment resistance. Treatment decisions are guided by disease severity, patient age, comorbidities, and treatment goals. FDA-approved systemic agents include ritlecitinib (JAK3/TEC inhibitor) and baricitinib (JAK1/2 inhibitor), which block inflammatory pathways to promote hair regrowth with favorable efficacy, though they require monitoring for potential adverse effects.

An expert discusses how alopecia areata affects approximately 2% of the population globally, with onset typically in childhood or early adulthood. Patients often present with autoimmune comorbidities (thyroid disorders, vitiligo, atopic dermatitis) and psychological distress. Diagnostic challenges include differentiating from other hair loss conditions and predicting disease course. Treatment difficulties involve unpredictable responses, lack of standardized protocols, and addressing both physical symptoms and psychological impact.

Panelists discuss the systemic treatment option tralokinumab for pediatric atopic dermatitis (AD), focusing on its mechanism of action, efficacy, safety, and role in improving outcomes for children with moderate to severe disease.

Panelists discuss the topical treatment option tapinarof for pediatric atopic dermatitis, examining its mechanism of action, efficacy, safety, and potential to improve management of the condition in children.

Panelists discuss how physicians can achieve optimal atopic dermatitis management by following American Academy of Dermatology (AAD) guidelines for systemic therapy selection while considering individual patient factors and treatment goals.

Panelists discuss how clinicians can evaluate the severity of atopic dermatitis through comprehensive assessment of symptoms, quality-of-life impact, and treatment response to guide decisions about transitioning patients to systemic therapy.

Independent pharmacies are closing at high rates, leaving many communities without essential health care access.

The panelist discusses how to optimize topical therapy selection and application strategies for a young man with mild atopic dermatitis to achieve symptom control and maintain skin barrier function.

The panelist discusses how to effectively communicate the benefits and potential adverse effects of dupilumab treatment to patients and their families to support informed decision-making.

Christophe Piketty, MD, PHD, provides a deeper look at the promise of nemolizumab in addressing unmet needs faced by patients with atopic dermatitis and prurigo nodularis.

Haws offers advice to female clinicians about leadership, collaboration, and the future of the aesthetics industry.

Christophe Piketty, MD, PHD, discusses the promising efficacy, novel mechanisms, and patient benefits of nemolizumab in targeting IL-31 for atopic dermatitis and prurigo nodularis.

Well Revolution’s partnership with City Chemist highlights how telehealth can sustain small businesses and improve patient care.

Professor Diamant Thaçi, MD, PhD, discusses findings from the ARCADIA and OLYMPIA clinical trial programs, highlighting nemolizumab’s rapid efficacy in treating atopic dermatitis and prurigo nodularis.

This collective initiative gives Mindy Haws, MD, and her team the ability to reach more women in a way that gives back and helps them succeed.

Mindy Haws, MD, spoke to Dermatology Times about the new videos, podcasts, and other resources LIMITLESS offers for women at all stages of their careers.

Panelists discuss the topical treatment option roflumilast for pediatric atopic dermatitis, exploring its mechanism of action, efficacy, safety, and potential role in managing the condition.

The panelist discusses how systemic atopic dermatitis therapies now emphasize targeted biologics and Janus kinase inhibitors, requiring personalized approaches, comprehensive monitoring, and holistic patient management.

The panelist discusses how a 28-year-old woman with moderate atopic dermatitis requires personalized, comprehensive management addressing hand involvement, corticosteroid concerns, and potential Janus kinase (JAK) inhibitor therapy, focusing on symptom relief, safety, and patient-specific factors.